Bharat Biotech to launch Covaxin in Q2 2021
Posted by
www.biotecnika.org
The company's vaccine candidate -Covaxin- has been developed in
collaboration with the Indian Council of Medical Research (ICMR) -
National Institute of Virology (NIV) using inactivated Sars-Cov-2, the
virus that causes COVID-19.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-to-launch-covaxin-in-q2-2021/articleshow/78979220.cms
Subscribe to:
Post Comments (Atom)
December 17, 2024 at 5:17 AM
Bharat Biotech’s Covaxin launch in Q2 is an exciting step toward combating the ongoing health crisis. As a student juggling multiple tasks, I often find it challenging to stay on top of everything. This is why I sometimes choose to hire someone to do my class for me. It’s a smart way to balance priorities while ensuring I stay on track with my academic responsibilities.
May 7, 2026 at 11:36 PM
It is fascinating to see the collaboration between Bharat Biotech and ICMR on Covaxin. As biotechnology moves toward global distribution, the role of clear communication becomes critical. Ensuring that clinical trial data and regulatory documents are handled by a professional NAATI Translator is essential for meeting Australian safety standards. Quality translation services are truly the bridge between scientific innovation and global public health
May 7, 2026 at 11:36 PM
Great update on the Covaxin launch timeline. For medical breakthroughs like this to reach diverse markets, accuracy in documentation is key. Many organizations in Australia rely on NAATI Translator expertise to ensure compliance. It’s a great reminder of how vital specialized translation services are to the biotech industry
Post a Comment